Terapia con Attinio-225 e PET DOTA per tumori neuroendocrini — Standard Johns Hopkins

• Terapia con Actinio-225
• Consultazione con un medico
• Esami del sangue
• Esame di follow-up
• Esame di biochimica del sangue

• Trasferimento aeroporto-clinica-aeroporto

ACTINIUM-225 DOTA ALPHA NEUROENDOCRINE PREMIUM PROGRAM

The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors.

This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a DOTA-based targeting molecule that binds specifically to somatostatin receptor–expressing tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity.

Before treatment, a specialized DOTA PET/CT scan is performed at our hospital to confirm that the tumor expresses the appropriate receptors and to evaluate disease distribution. Only patients who meet these molecular criteria are selected for Actinium-225 therapy, ensuring a personalized and precisely targeted treatment approach.

The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols.

The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and full traceability.

The treatment package includes nuclear medicine consultation, comprehensive blood testing to assess kidney, liver, and hematologic function, MAG-3 renal scintigraphy during the first cycle if clinically indicated, administration of Actinium-225 DOTA therapy, and structured medical follow-up by a nuclear medicine specialist.

The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety.

For patient comfort and convenience, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, allowing for a smooth and organized treatment experience.

This program provides a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled, internationally coordinated clinical framework.

• Coordinatore medico personale
• Organizzazione dei viaggi medici — prenotazione di biglietti aerei e camere d'albergo a prezzi speciali per i partner
• Tutela degli interessi dei pazienti durante il viaggio medico